Assessment of cognitive functions in psoriatic arthritis patients

Abstract

Uvod: Cilj istraživanja bio je procijeniti kognitivne funkcije u bolesnika sa psorijatičnim artritisom (PsA). Ispitanici i metode: U istraživanje presječnog tipa konsekutivno su uključeni bolesnici sa PsA (N= 67) i zdravi ispitanici (N= 69). Kognitivne funkcije procijenjene su pomoću Montrealskog testa kognitivne procjene (MoCA) i testa utiranja puta (TMT) A i B. Simptomi depresije i anksioznosti testirani su pomoću Beckovog inventara depresije-II te Upitnika anksioznosti kao stanja i osobine ličnosti. Učinjena je standardna klinička procjena PsA i psorijaze. Rezultati: Bolesnici sa PsA imali su značajno lošije rezultate na TMT-A testu (p˂0,01). Nije bilo razlike između skupina u rezultatima MoCA i TMT-B testa. Svi testovi procjene kognitivnih funkcija korelirali su s dobi ispitanika, a TMT-B dodatno s obrazovnim statusom. Nije nađena korelacija između testova procjene kognitivnih funkcija i kliničkih parametara psorijatične bolesti, depresije i anksioznosti. U regresijskoj analizi, dob ispitanika pokazala se značajnom u predviđanju rezultata MoCA testa, objašnjavajući oko 18% varijance. U bolesnika sa PsA primijećene su značajno više razine depresivnosti, anksioznosti i umora (p=0,02; 0,015; odnosno 0,004). Zaključak: Bolesnici sa PsA potencijalno imaju povišen rizik kognitivnog oštećenja. Potrebna su daljnja istraživanja kako bi se preciznije odredio rizik kognitivnog propadanja u PsA.Objective: The objective of this study was to assess cognitive functions in patients with psoriatic arthritis (PsA). Methods: Patients with PsA (N= 67) and healthy subjects (N= 69) were consecutively enrolled in this cross-sectional study. Cognitive functions were assessed using the Montreal Cognitive Assessment (MoCA) and the Trail Making Test (TMT) A and B. Depression and anxiety were evaluated using the Beck Depression Inventory-II and the State-Trait Anxiety Inventory. A standard clinical assessment of PsA and psoriasis was performed. Results: Patients with PsA scored significantly worse on the TMT-A test (p˂0.01). No differences in the MoCA and TMT-B scores were found. All cognitive assessment tests correlated with age, and TMT-B also correlated with educational status. No correlation was found between cognitive assessment tests and PsA disease-related parameters, depression or anxiety. In the regression analysis, age was found to be a significant predictor of the MoCA score, explaining 18% of the variance. Patients with PsA exhibited significantly higher levels of depression, anxiety and fatigue (p=0.02, 0.015, and 0.004, respectively). Conclusion: Patients with PsA may be at an increased risk of cognitive impairment. Further research is needed to specify the risk of cognitive decline in PsA